Lupin Limited, a global pharmaceutical company, has recently launched Glucagon for Injection USP in the United States to address severe hypoglycemia in patients with diabetes mellitus. This product, available in 1mg/vial emergency kits, is equivalent to Eli Lilly’s Glucagon for Injection, 1 mg/vial. The United States Food and Drug Administration (USFDA) approved Lupin’s Abbreviated New Drug Applications in June, paving the way for this launch.
Glucagon is primarily used to treat severe hypoglycemia in both pediatric and adult patients with diabetes mellitus. Additionally, it serves as a diagnostic aid during radiologic exams to temporarily inhibit gastrointestinal tract movement in adult patients. The market estimate for Glucagon for Injection USP, 1mg/vial emergency kit in the U.S. stands at approximately USD 122 million based on IQVIA MAT June 2025 data.
In addition to Glucagon, Lupin introduced Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the U.S. after receiving USFDA approval. This medication is indicated for various inflammatory conditions of the eye, such as allergic conjunctivitis and post-operative inflammation following ocular surgery. Lupin, headquartered in Mumbai, India, operates in over 100 markets globally, offering a wide range of pharmaceutical products, including branded and generic formulations, biotechnology products, and active pharmaceutical ingredients.
Lupin has a strong market presence in India and the U.S., focusing on various therapeutic areas like respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. With 15 modern manufacturing facilities and 7 research centers worldwide, Lupin continues to innovate and deliver high-quality healthcare solutions to patients globally.
Key Takeaways:
– Lupin’s introduction of Glucagon for Injection USP targets severe hypoglycemia in patients with diabetes mellitus in the U.S.
– The company’s diverse product portfolio includes pharmaceutical formulations, biotechnology products, and active pharmaceutical ingredients.
– Lupin’s global presence and strong market position in key therapeutic areas underscore its commitment to providing innovative healthcare solutions.
– The launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, further expands Lupin’s offerings in ophthalmic care, demonstrating its dedication to enhancing patient outcomes.
Read more on medicaldialogues.in